Galmed (GLMD) director David Sidransky reports initial share and option holdings

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. director David Sidransky filed an initial ownership report showing his equity position in the company. He directly holds 11,083 Ordinary Shares, along with several awards of Restricted Share Units (RSUs) that vest between 2026 and 2028, subject to his continued service.

The filing also lists stock options to purchase 111 Ordinary Shares at an exercise price of 558, expiring in 2031, and options on 166 Ordinary Shares at an exercise price of 2,080.8, expiring in 2028. The entry records holdings rather than new buy or sell transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SIDRANSKY DAVID

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	11,083	D
Restricted Share Units	1,042(1)	D
Restricted Share Units	11,666(2)	D
Restricted Share Units	12,500(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	07/15/2021	07/15/2031	Ordinary Shares	111	$558	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	166	$2,080.8	D

Explanation of Responses:

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ David Sidransky	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Galmed (GLMD) director David Sidransky report in this Form 3?

He reports his initial ownership in Galmed, including Ordinary Shares, restricted share units, and stock options. This Form 3 records his starting equity position as a director, rather than new purchases or sales of GLMD securities.

How many Galmed (GLMD) Ordinary Shares does David Sidransky hold?

The filing shows he directly holds 11,083 Ordinary Shares of Galmed Pharmaceuticals Ltd. These shares represent his current direct equity stake, separate from his restricted share units and stock options disclosed in the same Form 3 filing.

What stock options are disclosed for David Sidransky in Galmed (GLMD)?

He holds options to purchase 111 Ordinary Shares at an exercise price of 558, expiring in 2031, and options on 166 Ordinary Shares at an exercise price of 2,080.8, expiring in 2028, all reported as direct holdings.

What restricted share units are reported for David Sidransky at Galmed (GLMD)?

The Form 3 lists several RSU awards, including positions totaling 1,042, 11,666, and 12,500 restricted share units. Footnotes state these RSUs vest between 2026 and 2028, conditioned on his continued service with Galmed.

When do David Sidransky’s Galmed (GLMD) RSUs vest?

Footnotes state one RSU grant vests on August 7, 2026, another in four installments on May 12, 2026, November 12, 2026, May 12, 2027, and November 12, 2027, and a third from August 26, 2026 through August 26, 2028.

Does this Galmed (GLMD) Form 3 show insider buying or selling?

No specific buy or sell transactions are identified. The entries are labeled as holdings with unknown transaction codes, indicating this Form 3 primarily records David Sidransky’s existing Ordinary Shares, RSUs, and option positions as of the reporting date.